Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Feb
12
Today In Oncology
PSMA PET/CT-Guided Radiotherapy After Prostatectomy
Rural Populations Face Greater Barriers as Nonmedical Costs Hinder Cancer Clinical Trial Access
FDA Approves Pembrolizumab With Paclitaxel for Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
A New Risk Model for Esophagectomy Draws on the STS National Database
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo